A Randomized, Double-blind, Placebo-controlled, Parallel-designed Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Subjects With Stable Coronary Heart Disease
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2018
At a glance
- Drugs MEDI 5884 (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- Sponsors MedImmune
- 30 Nov 2018 Status changed from active, no longer recruiting to completed.
- 21 Sep 2018 Planned End Date changed from 10 Aug 2018 to 19 Nov 2018.
- 31 Aug 2018 Biomarkers information updated